Pulsed electromagnetic field (PEMF) therapy has been available in FDA-cleared devices since the 1970s. Since then, however, the technology has advanced by leaps and bounds. Targeted pulsed electromagnetic field (tPEMF™) therapy, patented by Assisi Animal Health, has revolutionized animal pain management, proving that PEMF can successfully manage countless painful and inflammatory conditions — all without the use of pharmaceuticals. In addition, PEMF’s ability to also manage behavioral conditions has become clear in just the last few years.
In 2021, a groundbreaking, double-blind, randomized, and placebo-controlled North Carolina State University study confirmed that targeted PEMF therapy clinically reduces canine separation anxiety (CSA). Using a unique electromagnetic signal, a revolutionary device called the Calmer Canine Anxiety Treatment System® targets the source of anxious symptoms: inflammation in the anxiety center of the brain. This means that, unlike fast-acting drugs, this device offers long-term relief.
After just four weeks of using this tPEMF device, almost two-thirds of dogs more than doubled the time they spent at rest when left alone. By the end of six weeks, dogs treated with tPEMF therapy showed a six-fold greater improvement in passive behaviors compared to dogs treated with a placebo device.
For the estimated 13 million dogs in the US alone that are suffering from CSA, this technology offers immense relief. For veterinary professionals, these findings mark a change in the way behavioral conditions can be safely and successfully managed, using Calmer Canine as an effective, well tolerated, and drug-free treatment option.
AUTHOR PROFILE
IVC Journal is a division of Redstone Media Group. Innovation is the key to veterinarians staying competitive and being able to provide their clients with the absolute best care possible. IVC Journal delivers the most up to date and compelling information available by bridging the gap between the traditional worlds of allopathic and integrative veterinary care.